Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Trial of Tocilizumab in Schizophrenia

Trial Profile

An Open-Label Trial of Tocilizumab in Schizophrenia

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2015

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Oct 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 04 Nov 2014 Planned End Date changed from 1 Sep 2013 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top